Inhibitors of leukotriene production

US9403830B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Asitha Abeywardane · Danbury, US
• Steven Richard Brunette · Ridgefield, US
• Michael J. Burke · West Haven, US
• Thomas Martin Kirrane, Jr. · Danbury, US
• Chuk Chui Man · Ridgefield, US
• Daniel Richard Marshall · Tucson, US
• Anil Kumar Padyana · Oxford, US
• Hossein Razavi · Danbury, US
• Robert Sibley · North Haven, US
• Lana Louise Smith Keenan · Poughquag, US
• Roger John Snow · Danbury, US
• Ronald John Sorcek · Bethel, US
• Hidenori Takahashi · Lagrangeville, US
• Steven John Taylor · Winchester, US
• Michael Robert Turner · Danbury, US
• Erick Richard Roush Young · Danbury, US
• Qiang Zhang · Dalian, CN
• Yunlong Zhang · North Haven, US
• Renee M. Zindell · New Milford, US

Key dates

• Filing date: Jul 16, 2013
• Grant date: Aug 2, 2016
• Expiry date: Oct 30, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of formula (I):or a pharmaceutically acceptable salt thereof, wherein A1, A2, L1 and B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.